Silexion Shareholders Approve 500M Share Increase and 1-for-24 Reverse Split
SLXN sits 23% above its 52-week low of $0.142 on light trading volume (0.1× avg).
Summary
Silexion shareholders approved a 500 million share authorized capital increase and a 1-for-24 reverse split, reversing their September rejections and clearing the way for new equity issuance and a Nasdaq bid-price cure.
Key Events · Corporate Governance and Compliance · SLXN
-
Shareholders Approve 500M Share Increase
Authorized capital rises from US$2,146,500 divided into 15,900,000 shares to US$69,646,500 divided into 515,900,000 shares of $0.135 par, approved 2,567,677 (95.4%) to 124,151 (4.6%).
-
1-for-24 Reverse Split Approved
Board fixed the ratio at 1-for-24 within the approved 1-for-15 to 1-for-25 range; shares consolidate to $3.24 par, approved 2,630,320 (97.7%) to 61,787 (2.3%).
-
Reversal of September Rejection
On September 25 shareholders rejected a 175M share increase and a 1-for-15 split; the larger 500M authorization passed this time.
-
Quorum Reached on Reconvened Meeting
Meeting adjourned October 19, 2026 for lack of quorum and reconvened October 26, 2026, where 2,697,489 shares (18.6% of outstanding) present constituted a quorum under Article 21.3.
Analysis · SLXN · Life Sciences
After shareholders rejected a 175M share increase and a 1-for-15 reverse split on September 25, they reversed course and approved a much larger 500,000,000-share authorization plus a 1-for-24 reverse split. The authorization removes the share-count ceiling that had blocked further equity issuance, and the reverse split is the company's main lever to cure the Nasdaq bid-price deficiency disclosed on September 25. Neither step raises cash by itself — the company still faces going-concern doubt and a Nasdaq delisting process — but it clears the structural path to raise money and stay listed. The dilution math is stark: authorized shares go from 15.9M to 515.9M, and against roughly 14.5M shares outstanding (2,697,489 = 18.6%), the headroom is enormous if the company issues into it.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.14 to $35.60. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.